Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 210

1.

Examining geographic accessibility to radiotherapy in Canada and Greenland for indigenous populations: Measuring inequities to inform solutions.

Chan J, Friborg J, Zubizarreta E, van Eck JW, Hanna TP, Bourque JM, Gaudet M, Dennis K, Olson R, Coleman CN, Petersen AJ, Grau C, Abdel-Wahab M, Brundage M, Slotman B, Polo A.

Radiother Oncol. 2020 Feb 14;146:1-8. doi: 10.1016/j.radonc.2020.01.023. [Epub ahead of print]

PMID:
32065874
2.

Promoting Effective Use of Patient-Reported Outcomes in Clinical Practice: Themes from a "Methods Toolkit" Paper Series.

Brundage MD, Wu AW, Rivera YM, Snyder C.

J Clin Epidemiol. 2020 Feb 13. pii: S0895-4356(19)30835-2. doi: 10.1016/j.jclinepi.2020.01.022. [Epub ahead of print]

PMID:
32061828
3.

Health-Related Internet Use Among Men With Prostate Cancer in Canada: Cancer Registry Survey Study.

Bender JL, Feldman-Stewart D, Tong C, Lee K, Brundage M, Pai H, Robinson J, Panzarella T.

J Med Internet Res. 2019 Nov 19;21(11):e14241. doi: 10.2196/14241.

4.

Access to radiotherapy among circumpolar Inuit populations.

Chan J, Friborg J, Chernov M, Cherkashin M, Grau C, Brundage M, Slotman B.

Lancet Oncol. 2019 Oct;20(10):e590-e600. doi: 10.1016/S1470-2045(19)30394-8. Epub 2019 Sep 30. Review.

PMID:
31579005
5.

Access to radiotherapy and its association with cancer outcomes in a high-income country: Addressing the inequity in Canada.

Chan J, Polo A, Zubizarreta E, Bourque JM, Hanna TP, Gaudet M, Dennis K, Brundage M, Slotman B, Abdel-Wahab M.

Radiother Oncol. 2019 Dec;141:48-55. doi: 10.1016/j.radonc.2019.09.009. Epub 2019 Sep 28.

PMID:
31575428
6.

The Value of Progression-Free Survival as a Treatment End Point Among Patients With Advanced Cancer: A Systematic Review and Qualitative Assessment of the Literature.

Raphael MJ, Robinson A, Booth CM, O'Donnell J, Palmer M, Eisenhauer E, Brundage M.

JAMA Oncol. 2019 Sep 26. doi: 10.1001/jamaoncol.2019.3338. [Epub ahead of print]

PMID:
31556921
7.

Employment outcomes for recent Canadian radiation oncology graduates.

Loewen SK, Halperin R, Perry G, McKenzie M, Vigneault E, Stuckless T, Brundage M.

Curr Oncol. 2019 Aug;26(4):e510-e514. doi: 10.3747/co.26.4925. Epub 2019 Aug 1.

8.

Medical Oncology Workload in Europe: One Continent, Several Worlds.

Seruga B, Sullivan R, Fundytus A, Hopman WM, Ocana A, Joffe J, Bodoky G, Le Tourneau C, Vanderpuye V, Lopes G, Hammad N, Sengar M, Brundage MD, Booth CM.

Clin Oncol (R Coll Radiol). 2020 Jan;32(1):e19-e26. doi: 10.1016/j.clon.2019.06.017. Epub 2019 Jul 16.

PMID:
31324474
9.

The radiation dose tolerance of the brachial plexus: A systematic review and meta-analysis.

Yan M, Kong W, Kerr A, Brundage M.

Clin Transl Radiat Oncol. 2019 Jun 14;18:23-31. doi: 10.1016/j.ctro.2019.06.006. eCollection 2019 Sep.

10.

Cancer care workforce in Africa: perspectives from a global survey.

Vanderpuye V, Hammad N, Martei Y, Hopman WM, Fundytus A, Sullivan R, Seruga B, Lopes G, Sengar M, Brundage MD, Booth CM.

Infect Agent Cancer. 2019 May 21;14:11. doi: 10.1186/s13027-019-0227-8. eCollection 2019.

11.

Taking Stock: The Canadian Association of Radiation Oncology 2017 Radiation Oncologist Workforce Study.

Loewen SK, Doll CM, Halperin R, Delouya G, Archambault J, Stuckless T, Brundage M.

Int J Radiat Oncol Biol Phys. 2019 Sep 1;105(1):42-51. doi: 10.1016/j.ijrobp.2019.04.035. Epub 2019 May 11.

PMID:
31082493
12.

National Trends and Dynamic Responses in the Canadian Radiation Oncology Workforce From 1990 to 2018.

Loewen SK, Doll CM, Halperin R, Parliament M, Pearcey RG, Milosevic MF, Bezjak A, Vigneault E, Brundage M.

Int J Radiat Oncol Biol Phys. 2019 Sep 1;105(1):31-41. doi: 10.1016/j.ijrobp.2019.04.019. Epub 2019 Apr 27.

PMID:
31039422
13.

A PRO-cision Medicine Methods Toolkit to Address the Challenges of Personalizing Cancer Care Using Patient-Reported Outcomes: Introduction to the Supplement.

Snyder C, Brundage M, Rivera YM, Wu AW.

Med Care. 2019 May;57 Suppl 5 Suppl 1:S1-S7. doi: 10.1097/MLR.0000000000001089.

PMID:
30985589
14.

Systematic Evaluation of Patient-Reported Outcome Protocol Content and Reporting in Cancer Trials.

Kyte D, Retzer A, Ahmed K, Keeley T, Armes J, Brown JM, Calman L, Gavin A, Glaser AW, Greenfield DM, Lanceley A, Taylor RM, Velikova G, Brundage M, Efficace F, Mercieca-Bebber R, King MT, Turner G, Calvert M.

J Natl Cancer Inst. 2019 Nov 1;111(11):1170-1178. doi: 10.1093/jnci/djz038.

15.

Medical oncology job satisfaction: Results of a global survey.

Raphael MJ, Fundytus A, Hopman WM, Vanderpuye V, Seruga B, Lopes G, Hammad N, Sengar M, Brundage MD, Sullivan R, Booth CM.

Semin Oncol. 2019 Feb;46(1):73-82. doi: 10.1053/j.seminoncol.2018.12.006. Epub 2019 Jan 2.

PMID:
30685074
16.

In proportion: approaches for displaying patient-reported outcome research study results as percentages responding to treatment.

Tolbert E, Brundage M, Bantug E, Blackford AL, Smith K, Snyder C; PRO Data Presentation Stakeholder Advisory Board.

Qual Life Res. 2019 Mar;28(3):609-620. doi: 10.1007/s11136-018-2065-3. Epub 2018 Nov 29.

PMID:
30498892
17.

A pilot evaluation of the expanded prostate cancer index composite for clinical practice (EPIC-CP) tool in Ontario.

Brundage MD, Barbera L, McCallum F, Howell DM.

Qual Life Res. 2019 Mar;28(3):771-782. doi: 10.1007/s11136-018-2034-x. Epub 2018 Oct 31.

PMID:
30382479
18.

Making a picture worth a thousand numbers: recommendations for graphically displaying patient-reported outcomes data.

Snyder C, Smith K, Holzner B, Rivera YM, Bantug E, Brundage M; PRO Data Presentation Delphi Panel.

Qual Life Res. 2019 Feb;28(2):345-356. doi: 10.1007/s11136-018-2020-3. Epub 2018 Oct 10.

19.

Evaluating Progression-Free Survival as a Surrogate Outcome for Health-Related Quality of Life in Oncology: A Systematic Review and Quantitative Analysis.

Kovic B, Jin X, Kennedy SA, Hylands M, Pedziwiatr M, Kuriyama A, Gomaa H, Lee Y, Katsura M, Tada M, Hong BY, Cho SM, Hong PJ, Yu AM, Sivji Y, Toma A, Xie L, Tsoi L, Waligora M, Prasad M, Bhatnagar N, Thabane L, Brundage M, Guyatt G, Xie F.

JAMA Intern Med. 2018 Dec 1;178(12):1586-1596. doi: 10.1001/jamainternmed.2018.4710.

20.

Improving patient outcomes and radiotherapy systems: A pan-Canadian approach to patient-reported outcome use.

Caissie A, Brown E, Olson R, Barbera L, Davis CA, Brundage M, Milosevic M.

Med Phys. 2018 Oct;45(10):e841-e844. doi: 10.1002/mp.12878. Epub 2018 Aug 24.

PMID:
30144083
21.

Picture This: Presenting Longitudinal Patient-Reported Outcome Research Study Results to Patients.

Tolbert E, Brundage M, Bantug E, Blackford AL, Smith K, Snyder C; PRO Data Presentation Stakeholder Advisory Board.

Med Decis Making. 2018 Nov;38(8):994-1005. doi: 10.1177/0272989X18791177. Epub 2018 Aug 22.

22.

Making their decisions for prostate cancer treatment: Patients' experiences and preferences related to process.

Feldman-Stewart D, Tong C, Brundage M, Bender J, Robinson J.

Can Urol Assoc J. 2018 Oct;12(10):337-343. doi: 10.5489/cuaj.5113. Epub 2018 May 28.

23.

Medical oncology workload in Canada: infrastructure, supports, and delivery of clinical care.

Fundytus A, Hopman WM, Hammad N, Biagi JJ, Sullivan R, Vanderpuye V, Seruga B, Lopes G, Sengar M, Brundage MD, Booth CM.

Curr Oncol. 2018 Jun;25(3):206-212. doi: 10.3747/co.25.3999. Epub 2018 Jun 28.

24.

Perioperative chemotherapy for urothelial carcinoma of the upper urinary tract: A systematic review and meta-analysis.

Gregg RW, Vera-Badillo FE, Booth CM, Mahmud A, Brundage M, Leveridge MJ, Hanna TP.

Crit Rev Oncol Hematol. 2018 Aug;128:58-64. doi: 10.1016/j.critrevonc.2018.05.005. Epub 2018 May 22. Review.

PMID:
29958631
25.

Quality of life as a prognostic indicator of survival: A pooled analysis of individual patient data from canadian cancer trials group clinical trials.

Ediebah DE, Quinten C, Coens C, Ringash J, Dancey J, Zikos E, Gotay C, Brundage M, Tu D, Flechtner HH, Greimel E, Reeve BB, Taphoorn M, Reijneveld J, Dirven L, Bottomley A; Canadian Cancer Trials Group and the European Organization for Research and Treatment of Cancer.

Cancer. 2018 Aug;124(16):3409-3416. doi: 10.1002/cncr.31556. Epub 2018 Jun 15.

26.

Evaluation of a widely available patient decision aid for the treatment of prostate cancer.

Feldman-Stewart D, Tong C, Brundage MD.

Patient Educ Couns. 2018 Oct;101(10):1761-1766. doi: 10.1016/j.pec.2018.04.015. Epub 2018 Apr 24.

PMID:
29729858
27.

Do radiation oncology outreach clinics affect the use of radiotherapy?

McLaughlin PY, Kong W, de Metz C, Hanna TP, Brundage M, Warde P, Gutierrez E, Mackillop WJ.

Radiother Oncol. 2018 Apr;127(1):143-149. doi: 10.1016/j.radonc.2017.11.014.

PMID:
29478762
28.

Evaluation of patient-reported outcome protocol content and reporting in UK cancer clinical trials: the EPiC study qualitative protocol.

Retzer A, Keeley T, Ahmed K, Armes J, Brown JM, Calman L, Copland C, Efficace F, Gavin A, Glaser A, Greenfield DM, Lanceley A, Taylor RM, Velikova G, Brundage M, Mercieca-Bebber R, King MT, Calvert M, Kyte D.

BMJ Open. 2018 Feb 3;8(2):e017282. doi: 10.1136/bmjopen-2017-017282.

29.

Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols: The SPIRIT-PRO Extension.

Calvert M, Kyte D, Mercieca-Bebber R, Slade A, Chan AW, King MT; the SPIRIT-PRO Group, Hunn A, Bottomley A, Regnault A, Chan AW, Ells C, O'Connor D, Revicki D, Patrick D, Altman D, Basch E, Velikova G, Price G, Draper H, Blazeby J, Scott J, Coast J, Norquist J, Brown J, Haywood K, Johnson LL, Campbell L, Frank L, von Hildebrand M, Brundage M, Palmer M, Kluetz P, Stephens R, Golub RM, Mitchell S, Groves T.

JAMA. 2018 Feb 6;319(5):483-494. doi: 10.1001/jama.2017.21903.

30.

Prostate cancer patients' experience and preferences for acquiring information early in their care.

Feldman-Stewart D, Tong C, Brundage M, Bender J, Robinson J.

Can Urol Assoc J. 2018 May;12(5):E219-E225. doi: 10.5489/cuaj.4754. Epub 2018 Feb 6.

31.

Quality of Life From Canadian Cancer Trials Group MA.17R: A Randomized Trial of Extending Adjuvant Letrozole to 10 Years.

Lemieux J, Brundage MD, Parulekar WR, Goss PE, Ingle JN, Pritchard KI, Celano P, Muss H, Gralow J, Strasser-Weippl K, Whelan K, Tu D, Whelan TJ.

J Clin Oncol. 2018 Feb 20;36(6):563-571. doi: 10.1200/JCO.2017.75.7500. Epub 2018 Jan 12. Erratum in: J Clin Oncol. 2018 May 20;36(15):1540.

32.

Analyzing environmental sustainability methods for use earlier in the product lifecycle.

Brundage MP, Bernstein WZ, Hoffenson S, Chang Q, Nishi H, Kliks T, Morris KC.

J Clean Prod. 2018;187. doi: 10.1016/j.jclepro.2018.03.187.

33.

Delivery of Global Cancer Care: An International Study of Medical Oncology Workload.

Fundytus A, Sullivan R, Vanderpuye V, Seruga B, Lopes G, Hammad N, Sengar M, Hopman WM, Brundage MD, Booth CM.

J Glob Oncol. 2018 Sep;(4):1-11. doi: 10.1200/JGO.17.00126. Epub 2017 Dec 15.

34.

Minimal clinically important differences in the EORTC QLQ-C30 and brief pain inventory in patients undergoing re-irradiation for painful bone metastases.

Raman S, Ding K, Chow E, Meyer RM, van der Linden YM, Roos D, Hartsell WF, Hoskin P, Wu JSY, Nabid A, Haas R, Wiggenraad R, Babington S, Demas WF, Wilson CF, Wong RKS, Zhu L, Brundage M.

Qual Life Res. 2018 Apr;27(4):1089-1098. doi: 10.1007/s11136-017-1745-8. Epub 2017 Nov 29.

PMID:
29188483
35.

OV21/PETROC: a randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer.

Provencher DM, Gallagher CJ, Parulekar WR, Ledermann JA, Armstrong DK, Brundage M, Gourley C, Romero I, Gonzalez-Martin A, Feeney M, Bessette P, Hall M, Weberpals JI, Hall G, Lau SK, Gauthier P, Fung-Kee-Fung M, Eisenhauer EA, Winch C, Tu D, MacKay HJ.

Ann Oncol. 2018 Feb 1;29(2):431-438. doi: 10.1093/annonc/mdx754.

36.

Gender differences in pain and patient reported outcomes: a secondary analysis of the NCIC CTG SC. 23 randomized trial.

Chow S, Ding K, Wan BA, Brundage M, Meyer RM, Nabid A, Chabot P, Coulombe G, Ahmed S, Kuk J, Dar AR, Mahmud A, Fairchild A, Wilson CF, Wu JSY, Dennis K, DeAngelis C, Wong RKS, Zhu L, Chow E.

Ann Palliat Med. 2017 Dec;6(Suppl 2):S185-S194. doi: 10.21037/apm.2017.08.12. Epub 2017 Aug 29.

37.

A systematic review and development of a classification framework for factors associated with missing patient-reported outcome data.

Palmer MJ, Mercieca-Bebber R, King M, Calvert M, Richardson H, Brundage M.

Clin Trials. 2018 Feb;15(1):95-106. doi: 10.1177/1740774517741113. Epub 2017 Nov 10.

PMID:
29124956
38.

Variation in Radiotherapy Referral and Treatment for High-risk Pathological Features after Radical Prostatectomy: Results from a Population-based Study.

Jin CJ, Hanna TP, Cook EF, Miao Q, Brundage MD.

Clin Oncol (R Coll Radiol). 2018 Jan;30(1):47-56. doi: 10.1016/j.clon.2017.10.009. Epub 2017 Nov 3.

PMID:
29103854
39.

Gender and age make no difference in the re-irradiation of painful bone metastases: A secondary analysis of the NCIC CTG SC.20 randomized trial.

Chow R, Ding K, Ganesh V, Meyer RM, van der Linden YM, Roos D, Hartsell WF, Hoskin P, Wu JSY, Nabid A, van Acht M, Wanders R, Babington S, Demas WF, Wilson CF, Wong RKS, Brundage M, Zhu L, Chow E.

Radiother Oncol. 2018 Mar;126(3):541-546. doi: 10.1016/j.radonc.2017.10.006. Epub 2017 Nov 5.

PMID:
29102263
40.

Presenting comparative study PRO results to clinicians and researchers: beyond the eye of the beholder.

Brundage M, Blackford A, Tolbert E, Smith K, Bantug E, Snyder C; PRO Data Presentation Stakeholder Advisory Board (various names and locations).

Qual Life Res. 2018 Jan;27(1):75-90. doi: 10.1007/s11136-017-1710-6. Epub 2017 Nov 2.

41.

Measuring the Quality of Personal Care in Patients Undergoing Radiotherapy for Prostate Cancer.

Foley KA, Groome PA, Feldman-Stewart D, Brundage MD, Foley JH, McArdle S, Mackillop WJ.

Clin Oncol (R Coll Radiol). 2017 Dec;29(12):827-834. doi: 10.1016/j.clon.2017.09.004. Epub 2017 Oct 9.

PMID:
29032863
42.

Patient Reported Outcomes After Radiation Therapy for Bone Metastases as a Function of Age: A Secondary Analysis of the NCIC CTG SC-Twenty-Three Randomized Trial.

Chow S, Ding K, Wan BA, Brundage M, Meyer RM, Nabid A, Chabot P, Coulombe G, Ahmed S, Kuk J, Dar AR, Mahmud A, Fairchild A, Wilson CF, Wu JSY, Dennis K, DeAngelis C, Wong RKS, Zhu L, Chow E.

Am J Hosp Palliat Care. 2018 Apr;35(4):718-723. doi: 10.1177/1049909117733435. Epub 2017 Sep 26.

PMID:
28950727
43.

Radiation therapy quality indicators for invasive breast cancer.

Best L, de Metz C, Olivotto IA, Roy I, Whelan T, Arsenault J, Brundage M.

Radiother Oncol. 2017 May;123(2):288-293. doi: 10.1016/j.radonc.2017.03.022. Epub 2017 Apr 10.

PMID:
28408054
44.

Quality of life with cediranib in relapsed ovarian cancer: The ICON6 phase 3 randomized clinical trial.

Stark DP, Cook A, Brown JM, Brundage MD, Embleton AC, Kaplan RS, Raja FA, Swart AMW, Velikova G, Qian W, Ledermann JA.

Cancer. 2017 Jul 15;123(14):2752-2761. doi: 10.1002/cncr.30657. Epub 2017 Mar 24.

45.

The Practice of Radiation Oncology in Canada.

Lalani N, Cummings B, Halperin R, Rakovitch E, Brundage M, Vigneault E, Milosevic M.

Int J Radiat Oncol Biol Phys. 2017 Apr 1;97(5):876-880. doi: 10.1016/j.ijrobp.2016.11.055. Epub 2016 Dec 14. No abstract available.

PMID:
28333001
46.

Directly Improving the Quality of Radiation Treatment Through Peer Review: A Cross-sectional Analysis of Cancer Centers Across a Provincial Cancer Program.

Rouette J, Gutierrez E, O'Donnell J, Reddeman L, Hart M, Foxcroft S, Mitera G, Warde P, Brundage MD; Cancer Care Ontario Radiation Oncology Program Leads; Pan-Canadian Peer Review Steering Committee.

Int J Radiat Oncol Biol Phys. 2017 Jul 1;98(3):521-529. doi: 10.1016/j.ijrobp.2016.10.017. Epub 2016 Oct 20.

PMID:
28258891
47.

Effect of Radiotherapy on Painful Bone Metastases: A Secondary Analysis of the NCIC Clinical Trials Group Symptom Control Trial SC.23.

McDonald R, Ding K, Brundage M, Meyer RM, Nabid A, Chabot P, Coulombe G, Ahmed S, Kuk J, Dar AR, Mahmud A, Fairchild A, Wilson CF, Wu JSY, Dennis K, DeAngelis C, Wong RKS, Zhu L, Chan S, Chow E.

JAMA Oncol. 2017 Jul 1;3(7):953-959. doi: 10.1001/jamaoncol.2016.6770.

48.

Preliminary evidence on the uptake, use and benefits of the CONSORT-PRO extension.

Mercieca-Bebber R, Rouette J, Calvert M, King MT, McLeod L, Holch P, Palmer MJ, Brundage M; International Society for Quality of Life Research (ISOQOL) Best Practice for PROs—Reporting Taskforce.

Qual Life Res. 2017 Jun;26(6):1427-1437. doi: 10.1007/s11136-017-1508-6. Epub 2017 Feb 7.

PMID:
28168602
49.

Adjuvant ipilimumab for stage III melanoma: the patient voice.

Brundage M, Hanna T.

Lancet Oncol. 2017 Mar;18(3):282-284. doi: 10.1016/S1470-2045(17)30003-7. Epub 2017 Feb 3. No abstract available.

PMID:
28163001
50.

What do these scores mean? Presenting patient-reported outcomes data to patients and clinicians to improve interpretability.

Snyder CF, Smith KC, Bantug ET, Tolbert EE, Blackford AL, Brundage MD; PRO Data Presentation Stakeholder Advisory Board.

Cancer. 2017 May 15;123(10):1848-1859. doi: 10.1002/cncr.30530. Epub 2017 Jan 13.

Supplemental Content

Loading ...
Support Center